Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Biogen Inc. Revenue & Financial Statements
Biogen Inc. reported revenue of $9.9B for the fiscal year ended December 31, 2025, up 2.2% year over year, with net income of $1.3B and diluted EPS of $8.79.
- Company
- Biogen Inc. BIIB · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 11.0B | 10.2B | 9.8B | 9.7B | 9.9B |
| Cost of revenue | 2.1B | 2.3B | 2.5B | 2.3B | 2.4B |
| Gross profit | 8.9B | 7.9B | 7.3B | 7.4B | 7.5B |
| Operating income | 2.8B | — | — | — | — |
| Pretax income | 1.3B | 1.7B | 1.1B | 1.1B | 331.3M |
| Net income | 1.7B | 3.0B | 1.2B | 1.6B | 1.3B |
| Diluted EPS | 10.40 | 20.87 | 7.97 | 11.18 | 8.79 |
| EBITDA | 3.3B | — | — | — | — |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.3B | 2.5B | 2.5B | 2.5B | 2.4B | 2.6B | 2.5B | 2.3B |
| Cost of revenue | 542.2M | 546.0M | 638.7M | 583.5M | 629.3M | 605.0M | 674.4M | 495.5M |
| Gross profit | 1.7B | 1.9B | 1.8B | 1.9B | 1.8B | 2.0B | 1.9B | 1.8B |
| Operating income | — | — | — | — | — | — | — | — |
| Pretax income | 464.8M | 698.7M | 451.0M | — | 311.2M | 744.0M | 557.3M | (56.0M) |
| Net income | 386.6M | 598.1M | 388.8M | 276.2M | 202.2M | 571.2M | 489.8M | (48.9M) |
| Diluted EPS | 2.70 | 4.00 | 2.66 | 1.83 | 1.64 | 4.33 | 3.17 | -0.35 |
| EBITDA | — | — | — | — | — | — | — | — |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 23.9B | 24.6B | 26.8B | 28.0B | 29.4B |
| Current assets | 7.9B | 9.8B | 6.9B | 7.5B | 9.0B |
| Cash & equivalents | — | — | — | — | — |
| Total liabilities | 12.9B | 11.2B | 12.0B | 11.3B | 11.2B |
| Current liabilities | 4.3B | 3.3B | 3.4B | 5.5B | 3.3B |
| Long-term debt | 6.3B | 6.3B | 6.9B | 6.3B | 6.3B |
| Total debt | 6.3B | 6.3B | 6.9B | 6.3B | 6.3B |
| Stockholders’ equity | 10.9B | 13.4B | 14.8B | — | — |
| Net debt | — | — | — | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 3.6B | 1.4B | 1.5B | 2.9B | 2.2B |
| Investing cash flow | (563.7M) | 1.6B | (4.1B) | (799.2M) | (1.4B) |
| Financing cash flow | (2.1B) | (1.7B) | 149.3M | (683.5M) | (301.9M) |
| Capital expenditure | 258.1M | 240.3M | 277.0M | 153.7M | 153.8M |
| Free cash flow | 3.4B | 1.1B | 1.3B | 2.7B | 2.1B |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 238.6M | 254.1M | 264.2M | 291.2M | 290.8M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every BIIB filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.